Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience
Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience
复制标题
DOI：
10.3109/10428194.2015.1094801
复制
发表时间：
2016-06-01
影响因子：
2.6
通讯作者：
Bociek, R. Gregory
中科院分区：
文献类型：
--
作者：
Bhatt, Vijaya R.;Loberiza, Fausto R., Jr.;Bociek, R. Gregory
这项回顾性研究 (N=169) 的目的是比较 1984 年至 2012 年间内布拉斯加州淋巴瘤研究组治疗的套细胞淋巴瘤 (MCL) 不同亚型的总生存 (OS)。在母细胞、弥漫性和结节性亚型之间，对包括干细胞移植 (SCT) 在内的各种治疗的总体缓解率相似 (p=0.44)。 5 年时，与结节型亚型相比，胚细胞型和弥漫型亚型的 OS 较差（总体 p=0.005）。在多变量分析中，母细胞亚型和弥漫性亚型具有相似的死亡风险（p = 0.14），而结节亚型与母细胞亚型相比具有较低的风险（HR 0.48，95％CI 0.27-0.87，p = 0.01）。 SCT 的使用与较低的死亡风险相关。在单变量分析中，母细胞亚型通过强化前期治疗具有更好的 OS。总之，母细胞亚型的 OS 比结节性 MCL 差，但通过使用 SCT 和可能的强化诱导治疗可能会有所改善。
The objective of this retrospective study (N=169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p=0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p=0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p=0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p=0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.